

ADMA (Asymmetric Dimethylarginine) ELISA Assay Kit

Catalog Number: ADM31-K01 96 Wells For Research Use Only (RUO). Not for use in clinical, diagnostic or therapeutic procedures. v. 2.0 (09.18.18)

> EAGLE BIOSCIENCES, INC. 20A Northwest Blvd., Suite 112, Nashua, NH 03063 Phone: 617-419-2019 . Fax: 617-419-1110 <u>WWW.EAGLEBIO.COM</u>



1. Introduction and Principle of the Test

The Eagle Biosciences ADMA (Asymmetric Dimethylarginine) ELISA Assay Kit is intended for the quantitative determination of ADMA (Asymmetric Dimethylarginine) in serum or plasma. The ADMA (Asymmetric Dimethylarginine) ELISA Kit is for research use only and not to be used in clinical, therapeutic or diagnostic procedures.

The vascular endothelium plays a central role in the regulation of vascular structure and function, mainly due to the formation of endothelium-derived nitric oxide (NO). NO has been named an "endogenous anti-atherogenic molecule" due to its diverse regulatory functions in vascular homeostasis. NO is formed by the enzyme NO synthetase (NOS) from the amino acid precursor L-arginine. NOS activity can be down-regulated by asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NOS.

The effects of ADMA on NO synthesis and NO-mediated pathophysiological processes have been described in numerous experimental studies. Moreover, elevated ADMA levels in plasma have been found in clinical studies including samples with hypercholesterolemia, hypertension, chronic heart failure, chronic renal failure and other internal disorders. Recent prospective and cross-sectional studies indicated that elevated ADMA levels are a risk factor for future cardiovascular events and total mortality. ADMA may have diagnostic relevance as a novel cardiovascular risk marker.

The competitive ADMA (Asymmetric Dimethylarginine) ELISA Assay Kit uses the microtiter plate format. ADMA is bound to the solid phase of the microtiter plate. ADMA in the samples is acylated and competes with solid phase bound ADMA for a fixed number of rabbit anti-ADMA antiserum binding sites. When the system is in equilibrium, free antigen and free antigen-antiserum complexes are removed by washing. The antibody bound to the solid phase ADMA is detected by anti-rabbit/peroxidase. The substrate TMB / peroxidase reaction is monitored at 450 nm. The amount of antibody bound to the solid phase ADMA is inversely proportional to the ADMA concentration of the sample.

2. Precautions

- ADMA (Asymmetric Dimethylarginine) ELISA Assay Kit is for research use only and not to be used in clinical, therapeutic or diagnostic procedures.
- Disposable gloves should be used.
- Material of animal origin used in the preparation of the ADMA (Asymmetric Dimethylarginine) ELISA Assay Kit has been obtained from animals certified as healthy but these materials should be handled as potentially infectious.



3. **Storage and Stability**

- On arrival, store the ADMA (Asymmetric Dimethylarginine) ELISA Assay Kit at 2-8 °C. Once opened the kit is stable until its expiry date. For stability of prepared reagents refer to Preparation of Reagents.
- Do not use components beyond the expiration date shown on the labels. •
- Do not mix various lots of the ADMA (Asymmetric Dimethylarginine) • ELISA Assay Kit component within an individual assay.

4. Contents of the Kit

4.	1 MT-Strips 8 wells each break apart precoated w ADMA			\$	strips			12 strips
4.2	Standards ²	1 – 6		C	AL 1 - 6			6 vials
	Each 4 ml, r	eady						
	for use							
	Concentratio	ons:						
	Standard	1	2	3	4	5	6]
	µmol/l	0	0.2	0.45	0.7	1.0	3.0	
4.3	Control 1 & Each 4 ml, re for use Rang q.c. certifica	eady je: see		(CON 1 & 2	2		2 vials
4.4	Acylation 3.5 ml, rea		e		ACYL-BU	FF		1 bottle
4.	5 Acylation lyophilised in 3.0 ml S combine th	, dissolve olvent bei	content fore use; i	•	ACYL-REA	AG		3 vials
4.6	Antiserum 7.0 ml, rea Rabbit-an	5			AS			1 vials
4.7	Enzyme Co 13 ml, read goat anti-r	dy for use			CONJ			1 vial
ADMA (Asymmetri ADM31-K01	c Dimethylargi	nine) ELIS.	A				www.E	agle B io.com

4.9	Substrate 13 ml TMB solution, ready for	SUB	1 vial
4.8	Wash Buffer 20 ml, concentrated Dilute content with dist. wat	WASH	1 bottle
4.10	Stop Solution 13 ml, ready for use Contains 0.3 M sulphuric aci	STOP d, not corrosive	1 vial
4.11	Reaction Plate for acylation	ACYL-PLATE	1 piece
4.12	Equalizing Reagent lyophilzed, dissolve content v water, dissolve carefully to m formation(see also 6.)		1 vial
4.1		SOLVENT SO eacts with many plastic materials in ot react with normal pipette tips a	5
4.	14 Foil 2 Pieces	FOIL	
Add	itional materials and equipm	ent required but not provided:	
• F	Pipettes (20, 25, 50, 100 and 20	0 µl)	
• N	<i>I</i> ulitpipette		

- Orbital shaker
- Microplate washing device
- Microplate photometer (450 nm)
- Vortex mixer
- Roll mixer

5. Sample Collection

5.1. Serum and Plasma

• The ADMA (Asymmetric Dimethylarginine) ELISA Assay can be performed with serum as well as with EDTA plasma.

- Hemolytic and lipemic samples should not be used in the ADMA (Asymmetric Dimethylarginine) ELISA Assay Kit.
- The samples can be stored up to 24 hours at 2 8 °C. For a longer storage (up to 24 months) the samples must be frozen at -20 °C
- Repeated freezing and thawing should be avoided.

6. Preparation of Reagents and Samples

6.1. Microtiter strips <u>STRIPS</u>

Before opening the packet of strip wells, allow it to stand at room temperature for at least 10 minutes. After opening, keep any unused wells in the original foil packet with the desiccant provided. Reseal carefully and store at 2-8 °C.

6.2 Wash Buffer WASH

Dilute the content with dist. water to a total volume of 1,000 ml. The diluted wash buffer has to be stored at 2 - 8 °C for a maximum of 4 weeks. For storage until exppiry date as give on the label the diluted wash buffer has to be kept frozen at -20°C.

6.3. Equalizing Reagent <u>EQUA-REAG</u>

Dissolve the content with 21.0 ml dist. water, mix shortly and leave on a roll mixer or orbital shaker for 20 minutes. Handle carefully in order to minimize foam formation. The reconstituted Equalizing Reagent should be stored frozen at -20 °C and is stable for a minimum of 1 year.

6.4. Acylation Reagent <u>ACYL-REAG</u>

Dissolve the content of one bottle in 3.0 ml Solvent and shake for 10 minutes on a orbital shaker. After use the reagent has to be discarded. The Acylation Reagent has always to be prepared immediately before use and is stable for a maximum of 3 hours. The second and third bottle allows a second and third run of the test. If the whole kit is to be used in one run it is recommended to pool the dissolved contents of the two vials of Acylation Reagent. Please note that Solvent reacts with many plastic materials including plastic trays. Solvent does not react with normal pipette tips and with glass devices.


Attention

Solvent is volatile and the dissolved Acylation Reagent evaporates quickly. Therefore, please do not use a tray with big surface together with a multichannel pipette for pipetting Acylation Reagent. Rather, use an Eppendorf multipipette with a yellow tip (or similar device), fill the syringe directly from the vial with dissolved Acylation Reagent and add well by well.

All other reagents are ready for use.

2

6.5. Preparation of Samples (Acylation)



- 1. Pipette each 20 μl standard 1 6, each 20 μl control 1 & 2 and each 20 μl sample into the respective wells of the Reaction Plate.
- 2. Pipette 20 µl Acylation Buffer into all wells.
- 3. Pipette 200 µl Equalizing Reagent into all wells.
- 4. Mix the reaction plate for 10 seconds.
- 5. Prepare Acylation Reagent just before use and pipette 50 µl prepared Acylation Reagent each into all wells, mix **immediately.**

Attention

Solvent is volatile and the dissolved Acylation Reagent evaporates quickly. Therefore, please do not use a tray with big surface together with a multichannel pipette for pipetting Acylation Reagent. Rather, use an Eppendorf multipipette with a yellow tip (or similar device), fill the syringe directly from the vial with dissolved Acylation Reagent and add well by well.

6. Incubate for 20 minutes at room temperature (approx. 20 °C) on an orbital shaker. Do not cover the wells or the plate; leave the plate open on the shaker.

Take each 25 µl for the ADMA ELISA.

7. Test Procedure ADMA ELISA

Bring all reagents to room temperature and mix them carefully, avoid development of foam.

7.1 Sample Incubation

- Pipette each 25 µl prepared Standards 1 to 6, 20 µl prepared controls and 25 µl prepared samples into the respective wells of the coated microtiter strips (duplicates are recommended).
- Pipette each 50 µl Antiserum into all wells and shake shortly on an orbital shaker.
- Cover the plate with adhesive foil and incubate Microtiter Strips for 90 minutes at 20 to 25°C on an orbital shaker with medium frequency.



7.2 Washing

Discard or aspirate the contents of the wells and wash thoroughly with each 300µl Wash Buffer (Shake shortly on an orbital shaker). Repeat the washing procedure 4 times. Remove residual liquid by tapping the inverted plate on clean absorbent paper.

7.3 Conjugate Incubation

Pipette each 100 µl enzyme conjugate into all wells. Incubate for 30 minutes at room temperature on an orbital shaker at medium frequency.

7.4 Washing

Repeat step 7.2.

7.5 Substrate Incubation

Pipette each 100 μ l Substrate into all wells and incubate for 25 \pm 5 minutes at room temperature on an orbital shaker with medium frequency.

7.6 Stopping

Pipette each 100 µl Stop Solution into all wells.

7.7 Reading


Read the optical density at 450 nm (reference wavelength between 570 and 650 nm) in a microplate photometer within 15 minutes.

8. Calculation of the Results

On a semilogarithmic graph paper the concentration of the standards (x-axis, logarithmic) are plotted against their corresponding optical density (y-axis, linear). Cubic spline, 4 parameter or similar iteration procedures are recommended for evaluation of the standard curve. The concentration of the controls and samples can be read directly from this standard curve by using their average optical density.

Conversion factor: 1 µmol ADMA/ 1=202 ng ADMA/ml

Typical standard curve:



9. Assay Characteristics

9.1 Expected Values

0.4 – 0.75 µmol/l (80 – 150 ng/ml)

The reference ranges given above should only be taken as a guideline. It is recommended that each laboratory should establish its own reference values.

9.2 Sensitivity

Lower Limit of Detection	Calculation
0.03 µmol / l	OD _{Cal1} – 3 x SD

9.3 Specificity (Cross Reactivity)

Substance	Cross Reactivity (%)
ADMA	100
SDMA	0.05
Monomethylarginine (NMMA)	1.93
Homoarginine	< 0.01
Arginine	0.03

9.4 Recovery after Spiking

	Range (µmol / I)	Mean (%)	Range (%)
EDTA-Plasma	0.43 - 1.55	99	90 – 107
Serum	0.54 - 1.72	92	87 – 102

9.5 Linearity

	Range (µmol / I)	Highest Dil.	Mean (%)	Range (%)
EDTA-Plasma	0.23 – 1.53	1:6 with water	99	92 – 105

9.6 Reproducibility

	Range (µmol / I)	Intra-Assay-CV
EDTA-Plasma	0.58 – 1.04	4.9 – 5.4 %

	Range (µmol / I)	Inter-Assay-CV
EDTA-Plasma	0.57 – 1.34	4.3 – 9.6 %

Literature using this ADMA (Asymmetric Dimethylarginine) ELISA kit

- Schulze F, Wesemann R, Schwedhelm E, Sydow K, Albsmeier J,Cooke JP, Böger RH. Determination of ADMA using a novel ELISA assay. Clin. Chem. Lab. Med. 2004; 42: 1377-1383
- Krempl TK, Kähler J, Maas R, Silberhorn L, Meinertz T, Böger RH. Elevation of asymmetric dimethylarginine (ADMA) in patients with unstable angina and recurrent cardiovascular events. Eur. Heart J. 2005; 26: 1846-1851
- Schulze F, Maas R, Freese R, Schwedhelm E, Silberhorn L, Böger RH. Determination of a reference value for N,N-dimethyl-L-arginine in 500 subjects. Eur. J. Clin. Invest. 2005; 35 : 622-626
- Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, Jachmann N, Post F, Peetz D, Bickel C, Cambien F, Tiret L, Münzel T. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ. Res. 2005; 97: e53-59
- O`Dwyer MJ, Dempsey F, Crowley V, Kelleher D, McManus R, Ryan T. Septic shock correlates with ADMA levels which may be influenced by a polymorphism in DDAH II: a prospective observational study. Crit. Care 2006; 10: (5): R139
- Antoniades C, Tousoulis D, Marinou K, Vasiliadou C, Tentolouris C, Bouras G, Pitsavos C, Stefanidis C. Asymmetrical dimethylarginine regulates endothelial

function in methionine-induced but not in chronic homocystinemia in humans: effect of oxidative stress and proinflammatory cytokines. Am. J. Clin. Nutr. 2006; 84: 781-788.

- Wang TZ., Chen WJ., Cheng WC., Lin JW., Chen MF., Lee YT. Relation of improvement in endothelium-dependent flowmediated vasodilation after Rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and Creactive protein in nondiabetic patients with the metabolic syndrome. Am. J. Cardiol. 2006; 9: 1057-1062
- Wanby P., Nilsson I., Brudin L., Nyhammar I., Gustafsson I., Carlsson M. Increased plasma levels of asymmetric dimethylarginine in patients with carotid stenosis: no evidence for the role of the common FABBP2 A54T gene polymorphism. Acta Neurol. Scand. 2007; 115: 90-96
- Konishi H, Sydow K, Cooke JP. Dimethylarginine dimethylaminohydrolase promotes endothelial repair after vascular injury J. Am. Coll. Cardiol. 2007; 49: 1099-1105
- Iribarren C, Husson G, Sydow K, Wang BY, Sidney S, Cooke JP. Asymmetric dimethyl-arginine and coronary artery calcification in young adults entering middle age: the CARDIA Study. Eur. J. Cardiovasc. Prev. Rehabil. 2007; 14:222-229
- Melikian N, Wheatcroft SB, Ogah OS, Murphy C, Chowienczyk PJ, Wierzbicki AS, Sanders TA, Jiang B, Duncan ER, Shah AM, Kearney MT. Asymmetric dimethylarginine and reduced nitric oxide bioavailability in young Black African men. Hypertension 2007; 49: 873-877
- Horowitz JD, Heresztyn T. An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: Methodological considerations. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007; epub ahead of print
- Korish AA, Arafah MM. Catechin combined with vitamins C and E ameliorates insulin resistance (IR) and atherosclerotic changes in aged rats with chronic renal failure (CRF). Arch. Gerontol. Geriatr. 2007; in press
- Charitidou C, Farmakiotis D, Zournatzi V, Pidonia I, Pegiou T, Karamanis N, Hatzistilianou M, Katsikis I, Panidis D. The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome. Atherosclerosis 2007; in press

General Literature

Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure Lancet 1992; 339: 572 - 575

Stühlinger M, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS. **Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor** J. Am. Med. Assoc. 2002; 287: 1420-1426

Zoccali C, Bode-Böger SM, Mallamaci F, Benedetto FA, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frölich JC, Böger RH.

Asymmetric dimethylarginine (ADMA): An endogenous inhibitor of nitric oxide synthase predicts mortality in end-stage renal disease (ESRD) Lancet 2001; 358: 2113-2117 Nijveldt RJ, Teerlink T, Van der Hoven B, Siroen MP, Kuik DJ, Rauwerda JA, van Leeuwen PA. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality Clin. Nutr. 2003; 22: 23-30

Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, Nicolaides KH. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop preeclampsia

Lancet 2003; 361: 1511-1517

Böger RH.

The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor Cardiovasc. Res. 2003; 59: 824-833

Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC.

Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention.

Eur Heart J. 2003; 24: 1912-1919

Pipetting Scheme Sample Preparation

	Standards	Control	Sample
Standard 1 - 6	20		
Control 1 & 2		20	
Sample			20
Acylation Buffer	20	20	20
Equalizing Reagent	200	200	200

shake for 10 seconds

freshly prepared Acylation	50	50	50
Reagent µl	50	50	50

Immediately incubate for 20 minutes at room temperature on an orbital shaker

Take each 25µl of the supernatant for the ELISA



Pipetting Scheme ELISA

		Standard	Control	Sample
Standard 1 - 6	μl	25		
Control 1 & 2	μl		25	
Sample	μl			25
Antiserum	μl	50	50	50

Cover with foil and incubate 90 minutes at room temperature on an orbital shaker.

wash 4 x with each 300 µl Wash Buffer

Enzyme Conjugat	μl	100	100	100	
-----------------	----	-----	-----	-----	--

shake for 30 minutes at room temperature

wash 4 x with each 300 µl Wash Buffer

Substrate µl	100	100	100
--------------	-----	-----	-----

shake for 25 ± 5 minutes at room temperature

Stop Solution µl	100 100	0 100
------------------	---------	-------

read absorbance at 450 nm



Warranty Information

Eagle Biosciences, Inc. warrants its Product(s) to operate or perform substantially in conformance with its specifications, as set forth in the accompanying package insert. This warranty is expressly limited to the refund of the price of any defective Product or the replacement of any defective Product with new Product. This warranty applies only when the Buyer gives written notice to the Eagle Biosciences within the expiration period of the Product(s) by the Buyer. In addition, Eagle Biosciences has no obligation to replace Product(s) as result of a) Buyer negligence, fault, or misuse, b) improper use, c) improper storage and handling, d) intentional damage, or e) event of force majeure, acts of God, or accident.

Eagle Biosciences makes no warranties, either expressed or implied, except as provided herein, including without limitation thereof, warranties as to marketability, merchantability, fitness for a particular purpose or use, or non-infringement of any intellectual property rights. In no event shall the company be liable for any indirect, incidental, or consequential damages of any nature, or losses or expenses resulting from any defective product or the use of any product. Product(s) may not be resold, modified, or altered for resale without prior written approval from Eagle Biosciences, Inc.

For further information about this kit, its application or the procedures in this kit insert, please contact the Technical Service Team at Eagle Biosciences, Inc. at <u>info@eaglebio.com</u> or at 866-411-8023.